# Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

> **NCT01095796** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 707 (actual)

## Conditions studied

- HIV
- HIV Infections

## Interventions

- **DRUG:** Stribild
- **DRUG:** Atripla
- **DRUG:** Stribild Placebo
- **DRUG:** Atripla Placebo

## Key facts

- **NCT ID:** NCT01095796
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-08
- **Final completion:** 2014-09
- **Target enrollment:** 707 (ACTUAL)
- **Last updated:** 2015-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01095796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01095796, "Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01095796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*